Statin drug use is not associated with prostate cancer risk in men who are regularly screened

Journal of Urology

Volumn 192, Issue 2, 2014, Pages 379-384

  Platz, Elizabeth A ^a   Tangen, Catherine M ^c   Goodman, Phyllis J ^c   Till, Cathee ^c   Parnes, Howard L ^b   Figg, William D ^b   Albanes, Demetrius ^b   Neuhouser, Marian L ^c   Klein, Eric A ^d   Lucia, M Scott ^e   Thompson, Ian M ^f   Kristal, Alan R ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

hydroxymethylglutaryl coA reductase inhibitors; mass screening; prostate; prostatic neoplasms; risk

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FINASTERIDE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ACETYLSALICYLIC ACID; CHOLESTEROL;

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DRUG USE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION; AGE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; FAMILY HISTORY; HEART INFARCTION; PROSPECTIVE STUDY;

HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MASS SCREENING; PROSTATE; PROSTATIC NEOPLASMS; RISK;

COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84904256453     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.01.095     Document Type: Article

References (20)

1. S. Bonovas, K. Filioussi, and N.M. Sitaras Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies Int J Cancer 123 2008 899
2. D.M. Boudreau, O. Yu, and J. Johnson Statin use and cancer risk: a comprehensive review Expert Opin Drug Saf 9 2010 603
3. W.R. Farwell, L.W. D'Avolio, and R.E. Scranton et al. Statins and prostate cancer diagnosis and grade in a veterans population J Natl Cancer Inst 103 2011 885
4. A. Lustman, S. Nakar, and A.D. Cohen et al. Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study Prostate Cancer Prostatic Dis 17 2014 6
5. M.S. Cyrus-David, A. Weinberg, and T. Thompson et al. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report J Urol 173 2005 1923
6. R.J. Hamilton, K.C. Goldberg, and E.A. Platz et al. The influence of statin medications on prostate-specific antigen levels J Natl Cancer Inst 100 2008 1511
7. A.M. Mondul, B. Caffo, and E.A. Platz Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: a simulation study Cancer Epidemiol 35 2011 e6
8. I. Thompson, P. Goodman, and C. Tangen et al. The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215
9. R.N. Lemaitre, C.D. Furberg, and A.B. Newman et al. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study Arch Intern Med 158 1998 1761
10. D. Siegel, J. Lopez, and J. Meier Use of cholesterol-lowering medications in the United States from 1991 to 1997 Am J Med 108 2000 496
11. P.J. Goodman, C.M. Tangen, and J.J. Crowley et al. Implementation of the Prostate Cancer Prevention Trial (PCPT) Control Clin Trials 25 2004 203
12. T.J. Murtola, T.L. Tammela, and J. Lahtela et al. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study Cancer Epidemiol Biomarkers Prev 16 2007 2226
13. P.F. Coogan, J.P. Kelly, and B.L. Strom et al. Statin and NSAID use and prostate cancer risk Pharmacoepidemiol Drug Saf 19 2010 752
14. J. Haukka, R. Sankila, and T. Klaukka et al. Incidence of cancer and statin usage-record linkage study Int J Cancer 126 2010 279
15. C.C. Chang, S.C. Ho, and H.F. Chiu et al. Statins increase the risk of prostate cancer: a population-based case-control study Prostate 71 2011 1818
16. T.J. Murtola, T.L. Tammela, and L. Maattanen et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial Int J Cancer 127 2010 1650
17. I. Khosropanah, S. Falahatkar, and B. Farhat et al. Assessment of atorvastatin effectiveness on serum PSA level in hypercholesterolemic males Acta Med Iran 49 2011 789
18. A.M. Mondul, E. Selvin, and A.M. De Marzo et al. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004 Cancer Causes Control 21 2010 671
19. B. Akduman, D.J. Tandberg, and C.I. O'Donnell et al. Effect of statins on serum prostate-specific antigen levels Urology 76 2010 1048
20. E.A. Platz, C. Till, and P.J. Goodman et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial Cancer Epidemiol Biomarkers Prev 18 2009 2807